SCYNEXIS Inc.'s (SCYX) Phase 1 single ascending dose and multiple ascending dose trial of intravenous SCY-247 has dosed the first participants.
SCY-247, a second-generation triterpenoid antifungal, is being developed as a treatment for invasive candidiasis (IC) and as a prophylaxis therapy for invasive fungal disease. The company expects to report results from the intravenous SCY-247trial this year.
Commenting on the development, David Angulo, President and Chief Executive Officer of SCYNEXIS, said, "An IV formulation of SCY-247 would provide additional flexibility for the optimal management of patients with invasive candidiasis and we are excited by the achievement of this important development milestone, which moves this innovative antifungal closer towards meeting the needs of patients suffering from difficult to treat severe fungal diseases."
In its oral formulation, SCY-247 showed promising results in a phase 1 single and multiple ascending dose study, demonstrating that oral administration can reach target efficacy exposures while maintaining good tolerability for the treatment and prevention of invasive fungal infections. The positive findings were reported in September 2025.
SCY-247 was granted both Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA in January of this year.
SCYX is currently trading at $0.71, up 0.37%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.